Romania
· Delayed Price · Currency is RON Antibiotice Statistics
Total Valuation
Antibiotice has a market cap or net worth of RON 1.63 billion. The enterprise value is 1.82 billion.
| Market Cap | 1.63B |
| Enterprise Value | 1.82B |
Important Dates
The next estimated earnings date is Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | Sep 25, 2025 |
Share Statistics
Antibiotice has 671.34 million shares outstanding. The number of shares has increased by 0.03% in one year.
| Current Share Class | 671.34M |
| Shares Outstanding | 671.34M |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 1.08% |
| Float | 117.94M |
Valuation Ratios
The trailing PE ratio is 16.76.
| PE Ratio | 16.76 |
| Forward PE | n/a |
| PS Ratio | 2.45 |
| PB Ratio | 1.76 |
| P/TBV Ratio | 1.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 26.99 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.06, with an EV/FCF ratio of -53.96.
| EV / Earnings | 18.65 |
| EV / Sales | 2.73 |
| EV / EBITDA | 12.06 |
| EV / EBIT | 17.57 |
| EV / FCF | -53.96 |
Financial Position
The company has a current ratio of 2.62, with a Debt / Equity ratio of 0.22.
| Current Ratio | 2.62 |
| Quick Ratio | 1.49 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | 1.37 |
| Debt / FCF | -6.11 |
| Interest Coverage | 22.46 |
Financial Efficiency
Return on equity (ROE) is 10.77% and return on invested capital (ROIC) is 6.18%.
| Return on Equity (ROE) | 10.77% |
| Return on Assets (ROA) | 5.14% |
| Return on Invested Capital (ROIC) | 6.18% |
| Return on Capital Employed (ROCE) | 9.10% |
| Revenue Per Employee | 491,576 |
| Profits Per Employee | 71,925 |
| Employee Count | 1,357 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.42 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +11.19% in the last 52 weeks. The beta is 0.12, so Antibiotice's price volatility has been lower than the market average.
| Beta (5Y) | 0.12 |
| 52-Week Price Change | +11.19% |
| 50-Day Moving Average | 2.05 |
| 200-Day Moving Average | 2.60 |
| Relative Strength Index (RSI) | 74.81 |
| Average Volume (20 Days) | 281,922 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Antibiotice had revenue of RON 666.58 million and earned 97.53 million in profits. Earnings per share was 0.15.
| Revenue | 666.58M |
| Gross Profit | 427.99M |
| Operating Income | 103.56M |
| Pretax Income | 99.33M |
| Net Income | 97.53M |
| EBITDA | 150.91M |
| EBIT | 103.56M |
| Earnings Per Share (EPS) | 0.15 |
Balance Sheet
The company has 21.42 million in cash and 206.13 million in debt, giving a net cash position of -184.71 million or -0.28 per share.
| Cash & Cash Equivalents | 21.42M |
| Total Debt | 206.13M |
| Net Cash | -184.71M |
| Net Cash Per Share | -0.28 |
| Equity (Book Value) | 926.95M |
| Book Value Per Share | 1.38 |
| Working Capital | 335.48M |
Cash Flow
In the last 12 months, operating cash flow was 60.57 million and capital expenditures -94.29 million, giving a free cash flow of -33.72 million.
| Operating Cash Flow | 60.57M |
| Capital Expenditures | -94.29M |
| Free Cash Flow | -33.72M |
| FCF Per Share | -0.05 |
Margins
Gross margin is 64.21%, with operating and profit margins of 15.54% and 14.63%.
| Gross Margin | 64.21% |
| Operating Margin | 15.54% |
| Pretax Margin | 14.90% |
| Profit Margin | 14.63% |
| EBITDA Margin | 22.64% |
| EBIT Margin | 15.54% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 0.89%.
| Dividend Per Share | 0.02 |
| Dividend Yield | 0.89% |
| Dividend Growth (YoY) | -75.21% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 49.43% |
| Buyback Yield | -0.03% |
| Shareholder Yield | 0.91% |
| Earnings Yield | 5.97% |
| FCF Yield | -2.06% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 13, 2013. It was a forward split with a ratio of 1.1819213313.
| Last Split Date | May 13, 2013 |
| Split Type | Forward |
| Split Ratio | 1.1819213313 |
Scores
Antibiotice has an Altman Z-Score of 4.27.
| Altman Z-Score | 4.27 |
| Piotroski F-Score | n/a |